Benzylpenicillin (Powder) Instructions for Use
ATC Code
J01CE01 (Benzylpenicillin)
Active Substance
Benzylpenicillin (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Penicillin antibiotic, destroyed by penicillinase
Pharmacotherapeutic Group
Systemic antibacterial agents; beta-lactam antibacterial agents, penicillins; beta-lactamase sensitive penicillins
Pharmacological Action
An antibiotic from the group of biosynthetic penicillins. It exerts a bactericidal effect by inhibiting the synthesis of the microbial cell wall.
It is active against gram-positive bacteria: Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae, Bacillus anthracis; gram-negative bacteria: Neisseria gonorrhoeae, Neisseria meningitidis; anaerobic spore-forming rods; as well as Actinomyces spp., Spirochaetaceae.
Strains of Staphylococcus spp. that produce penicillinase are resistant to the action of benzylpenicillin. It is destroyed in an acidic environment.
The procaine salt of benzylpenicillin is characterized by a longer duration of action compared to the potassium and sodium salts.
Pharmacokinetics
After intramuscular administration, it is rapidly absorbed from the injection site. It is widely distributed in body tissues and fluids. Benzylpenicillin penetrates well through the placental barrier and the blood-brain barrier when the meninges are inflamed.
The half-life (T1/2) is 30 minutes. It is excreted in the urine.
Indications
Treatment of diseases caused by microorganisms sensitive to benzylpenicillin: lobar and focal pneumonia, pleural empyema, sepsis, septicemia, pyemia, acute and subacute septic endocarditis, meningitis, acute and chronic osteomyelitis, infections of the urinary and biliary tracts, tonsillitis, purulent infections of the skin, soft tissues and mucous membranes, erysipelas, diphtheria, scarlet fever, anthrax, actinomycosis, treatment of purulent-inflammatory diseases in obstetric and gynecological practice, ENT diseases, eye diseases, gonorrhea, blennorrhea, syphilis.
ICD codes
| ICD-10 code | Indication |
| A22 | Anthrax |
| A36 | Diphtheria |
| A38 | Scarlet fever |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| A42 | Actinomycosis |
| A46 | Erysipelas |
| A50 | Congenital syphilis |
| A51 | Early syphilis |
| A52 | Late syphilis |
| A54 | Gonococcal infection |
| A54.3 | Gonococcal eye infection |
| G00 | Bacterial meningitis, not elsewhere classified |
| H10 | Conjunctivitis |
| H15.0 | Scleritis |
| H15.1 | Episcleritis |
| H16 | Keratitis |
| H20 | Iridocyclitis |
| H66 | Suppurative and unspecified otitis media |
| I33 | Acute and subacute endocarditis |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31 | Chronic rhinitis, nasopharyngitis and pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| J86 | Pyothorax (pleural empyema) |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K83.0 | Cholangitis |
| L01 | Impetigo |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M86 | Osteomyelitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N41 | Inflammatory diseases of prostate |
| N70 | Salpingitis and oophoritis |
| N71 | Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess) |
| N72 | Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis) |
| N73.5 | Unspecified female pelvic peritonitis |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A60.Z | Congenital syphilis, unspecified |
| 1A61.Z | Early syphilis, unspecified |
| 1A62.Z | Late syphilis, unspecified |
| 1A72.4 | Gonococcal eye infection |
| 1A7Z | Gonococcal infection, unspecified |
| 1B50 | Scarlet fever |
| 1B70.0Z | Erysipelas, unspecified |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B72.0 | Bullous impetigo |
| 1B72.1 | Nonbullous impetigo |
| 1B72.Z | Impetigo, unspecified |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1B97 | Anthrax |
| 1C10.Z | Actinomycosis, unspecified |
| 1C17.Z | Diphtheria, unspecified |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1D01.0Z | Bacterial meningitis, unspecified |
| 1G40 | Sepsis without septic shock |
| 9A60.Z | Conjunctivitis, unspecified |
| 9A71 | Infectious keratitis |
| 9A7Z | Diseases of the cornea, unspecified |
| 9A96.0 | Anterior uveitis, not associated with systemic diseases |
| 9A96.1 | Anterior uveitis, associated with systemic diseases |
| 9A96.Z | Anterior uveitis, unspecified |
| 9B50 | Episcleritis |
| 9B51 | Scleritis |
| AA9Z | Unspecified suppurative otitis media |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09 | Chronic rhinitis, nasopharyngitis or pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| CA44 | Pyothorax |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC13 | Cholangitis |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| GA01.Z | Inflammatory diseases of uterus, except cervix, unspecified |
| GA05.2 | Unspecified pelvic peritonitis in women |
| GA07.Z | Salpingitis and oophoritis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| XA5WW1 | Cervix uteri |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Powder
The dosage is individualized. It is administered intramuscularly, intravenously, subcutaneously, and intrathecally.
For intramuscular and intravenous administration in adults, the daily dose ranges from 250,000 to 60 million IU. The daily dose for children under 1 year of age is 50,000-100,000 IU/kg, over 1 year – 50,000 IU/kg; if necessary, the daily dose can be increased to 200,000-300,000 IU/kg, and for vital indications – up to 500,000 IU/kg. The frequency of administration is 4-6 times a day.
For intrathecal administration, depending on the disease and severity, adults receive 5,000-10,000 IU, children – 2,000-5,000 IU. The drug is dissolved in sterile water for injection or in 0.9% sodium chloride solution at the rate of 1 thousand IU/ml. Before injection (depending on the level of intracranial pressure), 5-10 ml of cerebrospinal fluid is withdrawn and added to the antibiotic solution in an equal ratio.
Subcutaneously, Benzylpenicillin is used for infiltrate block (100,000-200,000 IU in 1 ml of 0.25%-0.5% procaine solution).
The potassium salt of Benzylpenicillin is used only intramuscularly and subcutaneously, in the same doses as the sodium salt of benzylpenicillin.
The procaine salt of Benzylpenicillin is used only intramuscularly. The average therapeutic dose for adults: single dose – 300,000 IU, daily dose – 600,000 IU. For children under 1 year of age – 50,000-100,000 IU/kg/day, over 1 year – 50,000 IU/kg/day. The frequency of administration is 3-4 times a day.
The duration of treatment with benzylpenicillin, depending on the form and severity of the disease, can range from 7-10 days to 2 months or more.
Adverse Reactions
From the digestive system: diarrhea, nausea, vomiting.
Effects due to chemotherapeutic action: vaginal candidiasis, oral candidiasis.
From the central nervous system: when using benzylpenicillin in high doses, especially with intrathecal administration, neurotoxic reactions may develop: nausea, vomiting, increased reflex excitability, meningism symptoms, convulsions, coma.
Allergic reactions: fever, urticaria, skin rash, rash on mucous membranes, joint pain, eosinophilia, angioedema. Cases of anaphylactic shock with fatal outcome have been described.
Contraindications
Hypersensitivity to benzylpenicillin and other drugs from the group of penicillins and cephalosporins. Intrathecal administration is contraindicated in patients suffering from epilepsy.
Use in Pregnancy and Lactation
Use during pregnancy is possible only if the intended therapeutic benefit for the mother outweighs the potential risk to the fetus.
If it is necessary to use during lactation, the issue of discontinuing breastfeeding should be decided.
Use in Renal Impairment
Use with caution in patients with impaired renal function.
Pediatric Use
Can be used in children according to indications.
Special Precautions
Use with caution in patients with impaired renal function, heart failure, predisposition to allergic reactions (especially drug allergy), and with hypersensitivity to cephalosporins (due to the possibility of cross-allergy).
If no effect is observed 3-5 days after starting use, a switch to other antibiotics or combination therapy should be made.
Due to the possibility of fungal superinfection, it is advisable to prescribe antifungal drugs during treatment with benzylpenicillin.
It must be taken into account that the use of benzylpenicillin in subtherapeutic doses or premature termination of treatment often leads to the emergence of resistant strains of pathogens.
Drug Interactions
Probenecid reduces the tubular secretion of benzylpenicillin, resulting in an increased concentration of the latter in the blood plasma and an increased half-life.
With simultaneous use with antibiotics that have a bacteriostatic effect (tetracycline), the bactericidal effect of benzylpenicillin is reduced.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Powder for solution for intravenous and intramuscular administration 500 thousand IU: vial 1 or 50 pcs.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
| Benzylpenicillin | Powder for solution for intravenous and intramuscular administration 500 thousand IU: vial 1 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intravenous and intramuscular administration | 1 vial |
| Benzylpenicillin sodium salt | 500 thousand IU |
Vials (1) – cardboard boxes.
Vials (50) – cardboard boxes.
Powder for solution for intravenous and intramuscular administration 1 million IU: vial 1 pc.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
| Benzylpenicillin | Powder for solution for intravenous and intramuscular administration 1 million IU: vial 1 pc. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intravenous and intramuscular administration | 1 vial |
| Benzylpenicillin sodium salt | 1 million IU |
1 million IU – glass vials (1) – cardboard packs.
Powder for solution for intramuscular and subcutaneous administration 1 million IU: vial 1, 10 or 50 pcs.
Powder for solution for intramuscular and subcutaneous administration 500 thousand IU: vial 1, 10 or 50 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Forms
| Benzylpenicillin | Powder for solution for intramuscular and subcutaneous administration 1 million IU: vial 1, 10 or 50 pcs. | |
| Powder for solution for intramuscular and subcutaneous administration 500 thousand IU: vial 1, 10 or 50 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for intramuscular and subcutaneous administration white in color, with a faint characteristic odor.
| 1 vial | |
| Benzylpenicillin sodium | 1 million IU |
Vials (1) – cardboard packs.
Vials (10) – cardboard boxes.
Vials (50) – cardboard boxes (for hospitals).
Powder for preparation of solution for intramuscular and subcutaneous administration white in color, with a faint characteristic odor.
| 1 vial | |
| Benzylpenicillin sodium | 500 thousand IU |
Vials (1) – cardboard packs.
Vials (10) – cardboard boxes.
Vials (50) – cardboard boxes (for hospitals).
Powder for solution for injection 1 million IU: vial 1 or 10 pcs.
Powder for solution for injection 500 thousand IU: vial 1 or 10 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Forms
| Benzylpenicillin | Powder for solution for injection 1 million IU: vial 1 or 10 pcs. | |
| Powder for solution for injection 500 thousand IU: vial 1 or 10 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for injection white in color, with a faint characteristic odor.
| 1 vial | |
| Benzylpenicillin sodium | 1 million IU |
Vials (1) – cardboard packs.
Vials (10) – cardboard boxes.
Vials (50) – cardboard boxes (for hospitals).
Powder for preparation of solution for injection white in color, with a faint characteristic odor.
| 1 vial | |
| Benzylpenicillin sodium | 500 thousand IU |
Vials (1) – cardboard packs.
Vials (10) – cardboard boxes.
Vials (50) – cardboard boxes (for hospitals).
Powder for solution for injection 500000 IU: vial 1, 5, 10 or 50 pcs.
Powder for solution for injection 1000000 IU: vial 1, 5, 10 or 50 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Biokhimik, JSC (Russia)
Dosage Forms
| Benzylpenicillin | Powder for solution for injection 500000 IU: vial 1, 5, 10 or 50 pcs. | |
| Powder for solution for injection 1000000 IU: vial 1, 5, 10 or 50 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for injection fine-crystalline, white in color, with a faint characteristic odor.
| 1 vial | |
| Benzylpenicillin sodium (in terms of the active substance) | 500000 IU (0.3 g) |
Vials with a volume of 10 ml (1) – cardboard packs.
Vials with a volume of 10 ml (5) – cardboard packs.
Vials with a volume of 10 ml (10) – cardboard packs.
Vials with a volume of 10 ml (50) – cardboard boxes.
Powder for preparation of solution for injection fine-crystalline, white in color, with a faint characteristic odor.
| 1 vial | |
| Benzylpenicillin sodium (in terms of the active substance) | 1000000 IU (0.6 g) |
Vials with a volume of 10 ml (1) – cardboard packs.
Vials with a volume of 10 ml (5) – cardboard packs.
Vials with a volume of 10 ml (10) – cardboard packs.
Vials with a volume of 10 ml (50) – cardboard boxes.
Powder for solution for intravenous and intramuscular administration 1 mln.U: fl. 50 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
| Benzylpenicillin sodium salt | Powder for solution for intravenous and intramuscular administration 1 mln.U: fl. 50 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intravenous and intramuscular administration | 1 vial |
| Benzylpenicillin sodium salt | 1000000 IU |
1000000 IU – vials.
1000000 IU – vials (50) – cardboard packs.
Powder for solution for intravenous and intramuscular administration 250 thousand units: vial. 50 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
| Benzylpenicillin sodium salt | Powder for solution for intravenous and intramuscular administration 250 thousand units: vial. 50 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intravenous and intramuscular administration | 1 vial |
| Benzylpenicillin sodium salt | 250000 IU |
250000 IU – vials.
250000 IU – vials (50) – cardboard packs.
Powder for solution for intravenous and intramuscular administration 500 thousand IU: vial 50 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
| Benzylpenicillin sodium salt | Powder for solution for intravenous and intramuscular administration 500 thousand IU: vial 50 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intravenous and intramuscular administration | 1 vial |
| Benzylpenicillin sodium salt | 500000 IU |
500000 IU – vials.
500000 IU – vials (50) – cardboard packs.
Powder for solution for injection and topical use 500,000 IU: vial 1 or 10 pcs.
Powder for solution for injection and topical use 1,000,000 IU: vial 1 or 10 pcs.
Marketing Authorization Holder
Sintez PJSC (Russia)
Dosage Forms
| Benzylpenicillin sodium salt | Powder for solution for injection and topical use 500,000 IU: vial 1 or 10 pcs. | |
| Powder for solution for injection and topical use 1,000,000 IU: vial 1 or 10 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for injection and topical use crystalline, white or almost white in color.
| 1 vial | |
| Benzylpenicillin sodium (benzylpenicillin sodium salt) | 500000 IU (299.4 mg) |
500000 IU – glass vials with a capacity of 10 ml (1) – cardboard packs.
500000 IU – glass vials with a capacity of 20 ml (1) – cardboard packs.
500000 IU – glass vials with a capacity of 10 ml (10) – cardboard packs.
500000 IU – glass vials with a capacity of 20 ml (10) – cardboard packs.
Powder for preparation of solution for injection and topical use crystalline, white or almost white in color.
| 1 vial | |
| Benzylpenicillin sodium (benzylpenicillin sodium salt) | 1000000 IU (598.8 mg) |
1000000 IU – glass vials with a capacity of 10 ml (1) – cardboard packs.
1000000 IU – glass vials with a capacity of 20 ml (1) – cardboard packs.
1000000 IU – glass vials with a capacity of 10 ml (10) – cardboard packs.
1000000 IU – glass vials with a capacity of 20 ml (10) – cardboard packs.
Powder for solution for intramuscular and subcutaneous administration 500,000 IU: vial 1 or 10 pcs.
Powder for solution for intramuscular and subcutaneous administration 1,000,000 IU: vial 1 or 10 pcs.
Marketing Authorization Holder
Sintez PJSC (Russia)
Dosage Forms
| Benzylpenicillin sodium salt | Powder for solution for intramuscular and subcutaneous administration 500,000 IU: vial 1 or 10 pcs. | |
| Powder for solution for intramuscular and subcutaneous administration 1,000,000 IU: vial 1 or 10 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for intramuscular and subcutaneous administration crystalline, white or almost white in color.
| 1 vial | |
| Benzylpenicillin sodium salt | 500000 IU (299.4 mg) |
500000 IU – glass vials with a capacity of 10 ml (1) – cardboard packs.
500000 IU – glass vials with a capacity of 20 ml (1) – cardboard packs.
500000 IU – glass vials with a capacity of 10 ml (10) – cardboard packs.
500000 IU – glass vials with a capacity of 20 ml (10) – cardboard packs.
Powder for preparation of solution for intramuscular and subcutaneous administration crystalline, white or almost white in color.
| 1 vial | |
| Benzylpenicillin sodium salt | 1000000 IU (598.8 mg) |
1000000 IU – glass vials with a capacity of 10 ml (1) – cardboard packs.
1000000 IU – glass vials with a capacity of 20 ml (1) – cardboard packs.
1000000 IU – glass vials with a capacity of 10 ml (10) – cardboard packs.
1000000 IU – glass vials with a capacity of 20 ml (10) – cardboard packs.
Powder for solution for intravenous and intramuscular administration 1 million IU: vial 1, 10 or 50 pcs.
Marketing Authorization Holder
Vial, LLC (Russia)
Manufactured By
Shandong Weifang Pharmaceutical Factory, Co. Ltd. (China)
Dosage Form
| Benzylpenicillin sodium salt-Vial | Powder for solution for intravenous and intramuscular administration 1 million IU: vial 1, 10 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for intravenous and intramuscular administration | 1 vial |
| Benzylpenicillin sodium salt | 1 million IU |
1 million IU – vials.
1 million IU – vials (10) – cardboard boxes.
1 million IU – vials (50) – cardboard boxes.
Powder for solution for injection 1 million IU: fl. 40 pcs.
Marketing Authorization Holder
Kyivmedpreparat PJSC (Ukraine)
Dosage Form
| Benzylpenicillin-KMP | Powder for solution for injection 1 million IU: fl. 40 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for injection | 1 vial |
| Benzylpenicillin sodium salt | 1 million IU |
1 million IU – vials (40) – cardboard boxes.
Powder for solution for injection 500 thousand IU: fl. 40 pcs.
Marketing Authorization Holder
Kyivmedpreparat PJSC (Ukraine)
Dosage Form
| Benzylpenicillin-KMP | Powder for solution for injection 500 thousand IU: fl. 40 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for injection | 1 vial |
| Benzylpenicillin sodium salt | 500 thousand IU |
500 thousand IU – vials (40) – cardboard boxes.
